Table 1.
Demographic and clinical characteristics (n = 297)
| Characteristics | N (%) |
|---|---|
| Male, n (%) | 167 (56.2) |
| Age at diagnosis in years, mean ± SD | 64.3 ± 9.5 |
| >65 years, n (%) | 155 (52.2) |
| Charlson co‐morbidity index # , n (%) | |
| 2–3 | 100 (33.7) |
| 4–5 | 98 (33.0) |
| ≥ 6 | 99 (33.3) |
| Performance status, n (%) | |
| ECOG 0 | 115 (38.7) |
| ECOG 1 | 133 (44.8) |
| ECOG ≥2 | 8 (2.7) |
| Unknown | 41 (13.8) |
| Disease stage, n (%) | |
| IIA | 6 (2.0) |
| IIB | 27 (9.1) |
| IIIA | 58 (19.5) |
| IIIB | 72 (24.2) |
| IV | 134 (45.1) |
| Tumour histology, n (%) | |
| Squamous | 72 (24.2) |
| Non‐squamous | 186 (62.6) |
| Large cell | 6 (2.0) |
| Combined or unspecified | 33 (11.1) |
| Smoking status, n (%) | |
| Never | 14 (4.7) |
| Current/former | 270 (90.9) |
| Unknown | 13 (4.4) |
| Treatment intention, n (%) | |
| Curative/adjuvant | 152 (51.2) |
| Palliative | 145 (48.8) |
| Radiotherapy (RT) regimen, n (%) | |
| No thoracic RT | 162 (54.5) |
| Concurrent thoracic RT | 50 (16.8) |
| Sequential thoracic RT | 85 (28.7) |
| Carboplatin‐based chemotherapy, n (%) | 205 (69.0) |
| Number of cycles, median (IQR) | 3 (2–4) |
| Cumulative dose (mg), median (IQR) | 1780 (1125–2280) |
| Cisplatin‐based chemotherapy, n (%) | 133 (44.8) |
| Number of cycles, median (IQR) | 3 (2–4) |
| Cumulative dose (mg/m2), median (IQR) | 225 (150–277) |
| Renal function, eGFR, CKD‐EPI | |
| Median mL/min/1.73 m2, (IQR) | 89 (76–90) |
| <60 mL/min/1.73 m2, n (%) | 24 (8.1) |
| Serum albumin (g/L), median (IQR) | 40.1 (36.7–42.5) |
| <37.5 (g/L), n (%) | 81 (27.3) |
| ≥37.5 (g/L), n (%) | 190 (64.0) |
| Unknown | 26 (8.7) |
#
Charlson co‐morbidity index score provides a simple means to quantify the effect of co‐morbid illnesses, including cardiovascular diseases, chronic obstructive pulmonary disease, liver disease, and diabetes mellitus, among others and accounts for the aggregate effect if multiple concurrent diseases. A higher score indicates more co‐morbidities.
ECOG, Eastern Cooperative Oncology Group; eGFR, estimated glomerular filtration rate; IQR, interquartile range; RT, radiotherapy; SD, standard deviation.